We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effect of Deep Brain Stimulation (DBS) on Sleep Architecture in Patients With Movement Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01169324
Recruitment Status : Active, not recruiting
First Posted : July 26, 2010
Last Update Posted : April 6, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this prospective, participant-blinded trial is to determine the changes in sleep architecture in a cohort of subjects who have undergone deep brain stimulation (DBS) surgery for treatment of movement disorders such as moderate to advanced Parkinson's disease (PD), tremor, or dystonia. Our preliminary observational data suggest that unilateral subthalamic nucleus (STN) DBS improves subjective sleep quality in PD patients 6 months after the procedure. The cause of this improvement in sleep quality is unknown, and this study proposes the use of polysomnography (PSG) to test whether the improvement in sleep is independent of improvement in night-time mobility associated with DBS treatment of the motor symptoms of PD, tremor, or dystonia.

Condition or disease Intervention/treatment
Parkinson's Disease Tremor Dystonia Other: Alteration of DBS stimulator settings

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Other
Official Title: Effect of DBS on Sleep Architecture in Patients With Movement Disorders.
Study Start Date : July 2010
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017

Arms and Interventions

Arm Intervention/treatment
Experimental: DBS on
baseline settings
Other: Alteration of DBS stimulator settings
Alteration of DBS stimulator settings
No Intervention: DBS off
DBS off

Outcome Measures

Primary Outcome Measures :
  1. Sleep Efficiency [ Time Frame: 1 month ]
    This is the percentage of time the subject is in bed when he/she is actually asleep.

Secondary Outcome Measures :
  1. Wake after sleep onset (WASO) [ Time Frame: 1 month ]
    This is a measurement of the amount of time during polysomnography recording that the subject is awake after their initial sleep onset.

  2. Total Sleep Time [ Time Frame: 1 month ]
  3. Two timed motor tasks [ Time Frame: 1 month ]
    1. The subject will tap index finger between 2 points 30 cm apart on the table for 10 seconds.
    2. The subject will be timed as they rise from a chair, walk 7 meters, return to the chair, and sit down.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Prior DBS surgery for treatment of movement disorders such as PD, tremor, or dystonia.
  • Stable DBS stimulator settings and medication regimen for at least 6 weeks prior to the sleep studies.
  • Sleep dysfunction as measured by the Pittsburgh Sleep Quality Index (PSQI) (score >5) at the subject's baseline pre-surgical evaluation.

Exclusion Criteria:

  • Known narcolepsy
  • Other previous surgical treatment of Parkinson's disease, tremor, or dystonia (with the exception of DBS) including pallidotomy, thalamotomy, or gene therapy procedures.
  • Untreated obstructive sleep apnea. If obstructive sleep apnea is discovered during the first sleep study, the subject will be removed from the study. After they have been treated for at least 6 weeks with CPAP, they can re-start the study.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01169324

United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Sponsors and Collaborators
University of Alabama at Birmingham
Principal Investigator: Amy W Amara, MD, phD UAB Neurology
More Information

Responsible Party: Amy Amara, MD, Instructor, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT01169324     History of Changes
Other Study ID Numbers: F100528004
First Posted: July 26, 2010    Key Record Dates
Last Update Posted: April 6, 2017
Last Verified: April 2017

Keywords provided by Amy Amara, MD, University of Alabama at Birmingham:
Parkinson's disease

Additional relevant MeSH terms:
Parkinson Disease
Dystonic Disorders
Movement Disorders
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurologic Manifestations
Signs and Symptoms